Axsome stocktwits.

76.6% of Axsome Therapeutics shares are held by institutional investors. 24.5% of Axsome Therapeutics shares are held by insiders. Comparatively, 3.9% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is …83.15 -0.34(-0.41%) Gold 1,894.70 +7.40(+0.39%) Advertisement Axsome Therapeutics, Inc. (AXSM) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 70.19 -0.37 (-0.52%) At close:...Vanguard Group currently owns 3,111,500 shares of AXSM worth $138,835,000. Norges Bank also entered the scene as a new investor during the fourth quarter and purchased a stake in Axsome Therapeutics with an approximate value of $19,776,000. With these investments from various hedge funds and institutional investors …

StockTwits is a social media platform designed for sharing ideas between investors, traders, and entrepreneurs. The company was co-founded by Howard Lindzon and Soren Macbeth in 2009. The company received the first Shorty Award in the 2008 finance category. Time magazine listed the company as one of its 2010 "50 best websites." The company …Get the latest Axsome Therapeutics Inc. (AXSM) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.il y a 1 jour ... ... stocktwits · Email. Text Size; Normal; Large; Extra Large. Trading in financial instruments and/or cryptocurrencies involves high risks ...

The latest price target for Axsome Therapeutics ( NASDAQ: AXSM) was reported by Mizuho on Monday, August 28, 2023. The analyst firm set a price target for 100.00 expecting AXSM to rise to within ...

fairvalueforyou. 2. 10/4/2023 6:29:16 PM. Go to Msg #. Axsome Therapeutics, Inc. Message board - Online Community of active, educated investors researching and discussing Axsome Therapeutics, Inc. Stocks.Axsome Therapeutics stock price target raised to $76 from $49 at Mizuho. Sep. 7, 2022 at 6:38 a.m. ET by Tomi Kilgore.Axsome reported its Q1'23 earnings yesterday - net loss was $(0.26) per share. The company's 2 commercial products - newly approved Auvelity and Sunosi, acquired from Jazz Pharmaceuticals earned $29m. Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock. Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the closing of its ...Synergistic with the rest of Axsome’s late-stage psychiatry and neurology pipeline Strong efficacy profile in current indication Axsome intends to develop Sunosi for new indication: ADHD Phase 3 trial initiation planned in 2022 35 issued U.S. patents with expiries at least to 2037-2040; more than 10 pending U.S. applications

Axsome Therapeutics expects peak sales of between $1 billion and $3 billion in the U.S. for AXS-05 in this indication were it to be approved. The drug is also being investigated as a potential ...

Axsome Therapeutics. Market Cap. $3B. Today's Change. (1.68%) $1.15. Current Price. $69.75. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing ...

On today's stock market, AXSM stock surged 5.4%, closing at 77.73. Axsome shares briefly topped a buy point at 82.10 out of a consolidation, according to MarketSmith.com. BTAI stock popped 13.6% ...AXSM Earnings Date and Information. Axsome Therapeutics last announced its earnings results on August 7th, 2023. The reported ($1.00) EPS for the quarter, beating the consensus estimate of ($1.24) by $0.24. The business had revenue of $46.70 million for the quarter, compared to analyst estimates of $40.19 million.Get the latest Axsome Therapeutics Inc (AXSM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.83.15 -0.34(-0.41%) Gold 1,894.70 +7.40(+0.39%) Advertisement Axsome Therapeutics, Inc. (AXSM) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 70.19 -0.37 (-0.52%) At close:...Axsome AXSM announced that it is floating a secondary issue of 3 million shares of its common stock to the public at a price of $75.00 per share (excluding underwriting discounts). The public ...A major regulatory win could be in the making. Axsome Therapeutics ( AXSM 1.84%) is one of the few clinical-stage biopharma stocks that Wall Street remains confident in as 2022 gets under way. The ...

StockTwits · Financial Juice · LinkedIn. About MarketBeat. About · Press Room · Help and How-To · Advertising · Careers · Contact. Popular Tools. Company ...AXSM Axsome Therapeutics Inc 10,959 Watch Alerts $66.47 $0.04 (0.06%) Today $66.40 0.07 (0.10%) After Hours About Feed News Sentiment Earnings Fundamentals Axsome Therapeutics (AXSM, $66.51) Moving Average Convergence Divergence (MACD) Histogram turned negative on October 12, 2023Tickeron - Stocks • about 22 hours agoGeorge Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Axsome Therapeutics, Bristol Myers Squibb, and Tesla. The Motley Fool recommends DexCom ...6 Wall Street analysts have issued 1-year price targets for Avadel Pharmaceuticals' stock. Their AVDL share price forecasts range from $11.00 to $25.00. On average, they predict the company's stock price to reach $18.14 in the next twelve months. This suggests a possible upside of 65.4% from the stock's current price.View the top 10 symbols with the most trending streams on Stocktwits right now. Check back every five minutes for updates. Trending. Most Active. Watchers. Position. Symbol. Score. Last Price %Change. Watch. Join the conversation. This …Track Netlist Inc (NLST) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

Axsome's (AXSM) shares have surged 17.2% in the past six months, owing to the launch of its first product, Auvelity, in October last year. Also, the addition of Sunosi boosts its top line.

This is what happened for most early investors in Axsome Therapeutics (AXSM 4.26%). The company last year brought its first two products to market. If you'd invested $5,000 in the biotech five ...Get Our Latest Analysis on AXSM. Axsome Therapeutics Stock Performance. AXSM stock opened at $70.19 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 4.52 and a ...Overall, Axsome Therapeutics looks poised to earn at least a few approvals in the next two years and grow its revenue long after that. That's why the biotech still looks like a buy right now ...Links AXSM StockTwits. Show Market Indexes. Detailed Chart. Chart Settings. Overall. 80%. Bullish. 0%. Trade Quality. Long. 40%. Short. Breakout Long Short. Tap ...3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or remove ads. AXSM Axsome Therapeutics Inc 10,958 $68.60 $1.24 (1.84%) Today $68.61 0.01 (0.01%) After Hours About Feed News Sentiment Earnings Fundamentals Upcoming EPS November 9th, 2023 Pre-Market Period Q3'23 Estimated $-1.17 Reported -- Surprise -- Result N/AAxsome Therapeutics, Inc. has come a long way since its early year as a clinical-stage innovator. The company is enjoying early launch success for its two stellar medicines (Auvelity and Sunosi).StockTwits is a social network designed specifically for traders and investors to share ideas in real-time. The platform adds a nice spin to the old “stock market message boards” model with a more efficient platform and additional features. Read through this review to see if StockTwits is worth your time or if you’re better off avoiding ...

846.4k shares, +14.9% compared to typical daily volume over the past 6 months. Typical daily volume is 736.6k shares over the past 6 months. Typical: 10.87 pts (14.1%) occurs 25% of the time. Extreme: 14.13 pts (18.4%) occurs 5% of the time. A summary of bullish and bearish indicators.

Friday continued what has been a bad week for Axsome Therapeutics ( AXSM -0.52%) investors. The biotech company's stock closed at $24.31 on Thursday, opened at $24.04 on Friday and continued to ...

Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options.Axsome won regulatory approval for Auvelity and launched the drug in the fall of last year. Each drug could generate peak revenue of more than $1 billion, according to company and analyst forecasts.We are committed to developing products that meaningfully improve the lives of patients. Axsome is developing innovative treatments including AXS-05, AXS-07, AXS-12, and AXS‑14. learn about our pipeline. Axsome focuses on CNS conditions including depression, Alzheimer's disease agitation, migraine, narcolepsy and fibromyalgia.Axsome Therapeutics (NASDAQ:AXSM) is a great speculative biotech to look into. ... You can follow me on stocktwits.com under the name BiopharmaPro where I currently have (62.5K) followers. ...fairvalueforyou. 2. 10/4/2023 6:29:16 PM. Go to Msg #. Axsome Therapeutics, Inc. Message board - Online Community of active, educated investors researching and discussing Axsome Therapeutics, Inc. Stocks.Axsome Therapeutics Inc (AXSM) sentiment score, message volume, participation score and buzz level Advertisement 3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or remove ads. AXSM Axsome Therapeutics Inc 10,961 Watch …Axsome's (AXSM) shares have surged 17.2% in the past six months, owing to the launch of its first product, Auvelity, in October last year. Also, the addition of Sunosi boosts its top line.Therefore, he maintains a Buy rating for Axsome Therapeutics. In another report released on September 25, Piper Sandler also upgraded the stock to a Buy with a $90.00 price target.Technical Analysis for AXSM - Axsome Therapeutics, Inc. Buy or Sell? AXSM closed up 1.1 percent on Friday, September 1, 2023, on 75 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.Nov 6, 2022 · $66.51 $3.68 (5.24%) Today About Feed News Sentiment Earnings Fundamentals Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview.

Track AMC Entertainment Holdings (AMC) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsAXSM bought FDA approved SUNOSI from JAZZ in March. CNS Pipeline is AXS-05, AXS-07, AXS-12, AXS-14. AXS-05 is expected to be FDA approved in Q2 for Depression. AXSM’s new drug application (NDA) seeking approval for AXS-05 to treat MDD is under a priority review with the FDA. After a positive interaction with the regulatory agency’s ...NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous ...On October 13, 2023, the stock performance of AXSM (Axsome Therapeutics) was closely watched by investors. The day started with an opening price of $66.38, slightly lower than the previous day’s closing price of $66.51. Throughout the trading day, the stock experienced a range between $65.76 and $66.85. The trading volume for the day was ...Instagram:https://instagram. paycom login clientcyclebar westlakedragon claws rs3dr sebi documentary Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Edesa Biotech (EDSA) and Harmony Biosciences Holdings (HRMY). Feb. 14, 2023 at 6 ...Plan Highlights: This exclusive service plan includes. Customizable Scrolling Ticker, Portfolio. Manager, News & Trading alerts; Personal chat, email, voice & text support. Best Fit for Your Budget. Monthly - less than 80 cents per day! Yearly - … k98 forumgrape animals strain Axsome Therapeutics ( AXSM 1.09%), a clinical-stage biotech focused on the development of drugs for central nervous system disorders, had a seriously rough August. The biotech's shares slipped by ... ivie funeral home murphy nc obituaries 11 analysts have issued 1 year price objectives for Axsome Therapeutics' stock. Their AXSM share price forecasts range from $81.00 to $180.00. On average, they expect the company's share price to reach $102.40 in the next year. This suggests a …View the latest Axsome Therapeutics Inc. (AXSM) stock price, news, historical charts, analyst ratings and financial information from WSJ.